MARK REYNOLDS: Open Payments
NPI 1023052503 · DURHAM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$787,607 in 613 payments from 8 companies in 2025. Trend: 2023 $503,864 · 2024 $678,215 · 2025 $787,607
Speaker / faculty: $625,621Travel & lodging: $90,116Consulting: $59,936Food & beverage: $11,934
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 126 | $179,074 |
| Neurocrine BioSciences, Inc. | 85 | $160,652 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 92 | $120,495 |
| Teva Pharmaceuticals USA, Inc. | 112 | $119,671 |
| Alkermes, Inc. | 104 | $103,755 |
| Janssen Pharmaceuticals, Inc | 84 | $103,571 |
| Otsuka America Pharmaceutical, Inc. | 3 | $245 |
| Lundbeck LLC | 7 | $143 |
Products named: INGREZZA, COBENFY, CAPLYTA, UZEDY, INVEGA SUSTENNA, ARISTADA, LYBALVI, ABILIFY MAINTENA.
Industry payments across NC — which companies pay providers there.
